James Koh1,2, Run Zhang1, Sanziana Roman2, Quan-Yang Duh2, Jessica Gosnell2, Wen Shen2, Insoo Suh3, Julie A Sosa1,2. 1. Endocrine Neoplasia Laboratory, Department of Surgery, University of California at San Francisco, San Francisco, CA, USA. 2. Department of Surgery, University of California at San Francisco, San Francisco, CA, USA. 3. Department of Surgery, NYU Langone Health, New York, NY, USA.
Abstract
CONTEXT: The biochemical basis for clinical variability in primary hyperparathyroidism (PHPT) is poorly understood. OBJECTIVE: This study aimed to define parathyroid tumor biochemical properties associated with calcium-sensing failure in PHPT patients, and to relate differences in these profiles to variations in clinical presentation. METHODS: Preoperative clinical data from a sequential series of 39 patients undergoing surgery for PHPT at an endocrine surgery referral center in a large, public university hospital were evaluated for correlation to parathyroid tumor biochemical behavior. An intact tissue, ex vivo interrogative assay was employed to evaluate the calcium-sensing capacity of parathyroid adenomas relative to normal donor glands. Tumors were functionally classified based on calcium dose-response curve profiles, and clinical parameters were compared among the respective classes. Changes in the relative expression of 3 key components in the calcium/parathyroid hormone (PTH) signaling axis-CASR, RGS5, and RCAN1-were evaluated as potential mechanisms for calcium-sensing failure. RESULTS: Parathyroid adenomas grouped into 3 distinct functional classes. Tumors with diminished calcium sensitivity were the most common (18 of 39) and were strongly associated with reduced bone mineral density (P = 0.0009). Tumors with no calcium-sensing deficit (11 of 39) were associated with higher preoperative PTH (P = 0.036). A third group (6/39) displayed a nonsigmoid calcium/PTH response curve; 4 of these 6 tumors expressed elevated RCAN1. CONCLUSION: Calcium-sensing capacity varies among parathyroid tumors but downregulation of the calcium-sensing receptor (CASR) is not an obligate underlying mechanism. Differences in tumor calcium responsiveness may contribute to variations in PHPT clinical presentation.
CONTEXT: The biochemical basis for clinical variability in primary hyperparathyroidism (PHPT) is poorly understood. OBJECTIVE: This study aimed to define parathyroid tumor biochemical properties associated with calcium-sensing failure in PHPT patients, and to relate differences in these profiles to variations in clinical presentation. METHODS: Preoperative clinical data from a sequential series of 39 patients undergoing surgery for PHPT at an endocrine surgery referral center in a large, public university hospital were evaluated for correlation to parathyroid tumor biochemical behavior. An intact tissue, ex vivo interrogative assay was employed to evaluate the calcium-sensing capacity of parathyroid adenomas relative to normal donor glands. Tumors were functionally classified based on calcium dose-response curve profiles, and clinical parameters were compared among the respective classes. Changes in the relative expression of 3 key components in the calcium/parathyroid hormone (PTH) signaling axis-CASR, RGS5, and RCAN1-were evaluated as potential mechanisms for calcium-sensing failure. RESULTS: Parathyroid adenomas grouped into 3 distinct functional classes. Tumors with diminished calcium sensitivity were the most common (18 of 39) and were strongly associated with reduced bone mineral density (P = 0.0009). Tumors with no calcium-sensing deficit (11 of 39) were associated with higher preoperative PTH (P = 0.036). A third group (6/39) displayed a nonsigmoid calcium/PTH response curve; 4 of these 6 tumors expressed elevated RCAN1. CONCLUSION: Calcium-sensing capacity varies among parathyroid tumors but downregulation of the calcium-sensing receptor (CASR) is not an obligate underlying mechanism. Differences in tumor calcium responsiveness may contribute to variations in PHPT clinical presentation.
Authors: E M Brown; D G Gardner; M F Brennan; S J Marx; A M Spiegel; M F Attie; R W Downs; J L Doppman; C D Aurbach Journal: Am J Med Date: 1979-06 Impact factor: 4.965
Authors: Heshan Peiris; Ravinarayan Raghupathi; Claire F Jessup; Mark P Zanin; Daisy Mohanasundaram; Kimberly D Mackenzie; Tim Chataway; Jennifer N Clarke; John Brealey; P Toby Coates; Melanie A Pritchard; Damien J Keating Journal: Endocrinology Date: 2012-09-25 Impact factor: 4.736
Authors: Pamela Howson; Schelto Kruijff; Ahmad Aniss; Thomas Pennington; Anthony J Gill; Tristan Dodds; Leigh W Delbridge; Stan B Sidhu; Mark S Sywak Journal: Endocr Pathol Date: 2015-09 Impact factor: 3.943
Authors: Munro Peacock; John P Bilezikian; Preston S Klassen; Matthew D Guo; Stewart A Turner; Dolores Shoback Journal: J Clin Endocrinol Metab Date: 2004-11-02 Impact factor: 5.958
Authors: John P Bilezikian; Maria Luisa Brandi; Richard Eastell; Shonni J Silverberg; Robert Udelsman; Claudio Marcocci; John T Potts Journal: J Clin Endocrinol Metab Date: 2014-08-27 Impact factor: 5.958
Authors: James Koh; Joyce A Hogue; Yuli Wang; Matthew DiSalvo; Nancy L Allbritton; Yuhong Shi; John A Olson; Julie A Sosa Journal: J Cell Mol Med Date: 2015-12-05 Impact factor: 5.310